Key statistics
As of last trade Cue Biopharma Inc (1UC:FRA) traded at 1.58, -43.93% below its 52-week high of 2.82, set on Dec 11, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.58 |
---|---|
High | 1.58 |
Low | 1.58 |
Bid | 1.58 |
Offer | 1.66 |
Previous close | 1.69 |
Average volume | 11.00 |
---|---|
Shares outstanding | 60.21m |
Free float | 59.88m |
P/E (TTM) | -- |
Market cap | 103.56m USD |
EPS (TTM) | -0.9743 USD |
Data delayed at least 15 minutes, as of Nov 11 2024 08:59 GMT.
More ▼
Announcements
- Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting
- Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
- Cue Biopharma Announces Pricing of $12.0 Million Public Offering
- Cue Biopharma Announces Proposed Public Offering
- Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer
- Cue Biopharma to Present at The Promise of Interleukin-2 Therapy Conference
- Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
- Cue Biopharma to Host Business Update Call and Webcast
- Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements
- Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
More ▼